MUMBAI, India, Jan. 23 -- Intellectual Property India has published a patent application (202531087093 A) filed by Guru Nanak Institute Of Pharmaceutical Science And Technology, Kolkata, West Bengal, on Sept. 12, 2025, for 'method and composition comprising silver nanoparticle-loaded sln films for prolonged topical antimicrobial action.'
Inventor(s) include Dr. Debabrata Ghosh Dastidar; Arunima Das; and Dipanwita Mukhopadhyay.
The application for the patent was published on Jan. 23, under issue no. 04/2026.
According to the abstract released by the Intellectual Property India: "The present invention introduces a novel silver nanoparticle (AgNP) loaded film for topical application, specifically engineered to overcome the critical challenges of increasing antibiotic resistance and the inherent aggregation and cytotoxicity issues associated with unencapsulated AgNPs. This innovative drug delivery system involves the meticulous synthesis and encapsulation of AgNPs within solid lipid nanoparticles (SLNs) to form stable AgNP@SLN complexes, which are subsequently integrated into a biocompatible polymeric film matrix. Comprehensive characterization studies confirm the successful development and superior properties of this formulation. Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM) analyses demonstrate the effective encapsulation of AgNPs within SLNs, maintaining nanoparticle integrity and preventing aggregation upon release, with encapsulated AgNPs showing significantly enhanced stability compared to standalone AgNPs. UV-Visible spectroscopy further confirms a high loading efficiency of approximately 93% of AgNPs within the SLNs. Physical evaluations, including Fourier Transform Infrared (FTIR) spectroscopy, Scanning Electron Microscopy (SEM), Energy-Dispersive X-ray Spectroscopy (EDX), Differential Scanning Calorimetry (DSC), and X-ray Diffraction (XRD), collectively validate the successful integration of AgNPs into the lipid matrix and film, confirming their physicochemical stability. Crucially, in vitro drug release studies reveal a sustained release profile, with 96.57% of silver nanoparticles released from the AgNP@SLN loaded film over 72 hours, governed by a non-Fickian transport mechanism. Antimicrobial assays against both Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria demonstrate significantly superior inhibitory efficacy of the AgNP@SLN loaded films compared to unencapsulated AgNPs, evidenced by remarkably lower Minimum Inhibitory Concentration (MIC) and IC50 values. This enhanced therapeutic performance is directly attributable to the improved stability, sustained release, and optimized interaction facilitated by the SLN encapsulation within the film. This invention thus provides a highly promising, stable, and effective alternative for topical antimicrobial therapy, mitigating the risks of aggregation and toxicity while maximizing therapeutic benefits."
Disclaimer: Curated by HT Syndication.
